Progress report on the first sub-Saharan Africa trial of newer versus older antihypertensive drugs in native black patients

Augustine N Odili, Birinus Ezeala-Adikaibe, Mouhamadou B Ndiaye, Benedict C Anisiuba, Marius M Kamdem, Chinwuba K Ijoma, Joseph Kaptue, Hilaire J Boombhi, Philip M Kolo, Elvis N Shu, Lutgarde Thijs, Jan A Staessen, Babatunde A Omotoso, Samuel Kingue, Serigne A Ba, Daniel Lemogoum, Jean-René M'Buyamba-Kabangu, Ifeoma I Ulasi, Augustine N Odili, Birinus Ezeala-Adikaibe, Mouhamadou B Ndiaye, Benedict C Anisiuba, Marius M Kamdem, Chinwuba K Ijoma, Joseph Kaptue, Hilaire J Boombhi, Philip M Kolo, Elvis N Shu, Lutgarde Thijs, Jan A Staessen, Babatunde A Omotoso, Samuel Kingue, Serigne A Ba, Daniel Lemogoum, Jean-René M'Buyamba-Kabangu, Ifeoma I Ulasi

Abstract

Background: The epidemic surge in hypertension in sub-Saharan Africa is not matched by clinical trials of antihypertensive agents in Black patients recruited in this area of the world. We mounted the Newer versus Older Antihypertensive agents in African Hypertensive patients (NOAAH) trial to compare, in native African patients, a single-pill combination of newer drugs, not involving a diuretic, with a combination of older drugs including a diuretic.

Methods: Patients aged 30 to 69 years with uncomplicated hypertension (140 to 179/90 to 109 mmHg) and ≤2 associated risk factors are eligible. After a four week run-in period off treatment, 180 patients have to be randomized to once daily bisoprolol/hydrochlorothiazide 5/6.25 mg (R) or amlodipine/valsartan 5/160 mg (E). To attain blood pressure <140/<90 mmHg during six months, the doses of bisoprolol and amlodipine should be increased to 10 mg/day with the possible addition of up to 2 g/day α-methyldopa.

Results: At the time of writing of this progress report, of 206 patients enrolled in the run-in period, 140 had been randomized. At randomization, the R and E groups were similar (P ≥ 0.11) with respect to mean age (50.7 years), body mass index (28.2 kg/m(2)), blood pressure (153.9/91.5 mmHg) and the proportions of women (53.6%) and treatment naïve patients (72.7%). After randomization, in the R and E groups combined, blood pressure dropped by 18.2/10.1 mmHg, 19.4/11.2 mmHg, 22.4/12.2 mmHg and 25.8/15.2 mmHg at weeks two (n = 122), four (n = 109), eight (n = 57), and 12 (n = 49), respectively. The control rate was >65% already at two weeks. At 12 weeks, 12 patients (24.5%) had progressed to the higher dose of R or E and/or had α-methyldopa added. Cohort analyses of 49 patients up to 12 weeks were confirmatory. Only two patients dropped out of the study.

Conclusions: NOAAH (NCT01030458) demonstrated that blood pressure control can be achieved fast in Black patients born and living in Africa with a simple regimen consisting of a single-pill combination of two antihypertensive agents. NOAAH proves that randomized clinical trials of cardiovascular drugs in the indigenous populations of sub-Saharan Africa are feasible.

Figures

Figure 1
Figure 1
Trial profile based on data available on 14 April 2011.
Figure 2
Figure 2
Number of patients screened, enrolled and randomized on 14 April 2011. The horizontal dotted line indicates the number of patients to be randomized.
Figure 3
Figure 3
Systolic blood pressure (A), diastolic blood pressure (B) and the proportion of patients controlled (C) during the course of the trial. For this analysis the two treatment groups were combined and all available data were used. Blood pressure control is a level below 140 mmHg systolic and 90 mmHg diastolic.
Figure 4
Figure 4
Systolic blood pressure (A), diastolic blood pressure (B) and the proportion of patients controlled (C) during the course of the trial. For this cohort analysis the two treatment groups are combined and the number of patients was constant in each of the data points (n = 49). Blood pressure control is a level below 140 mmHg systolic and 90 mmHg diastolic.

References

    1. Reddy KS, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation. 1998;97:596–601. doi: 10.1161/01.CIR.97.6.596.
    1. Bonita R, Reddy S, Galbraith S, Bettcher D, MacIntyre M, Peden M, Rozenberg M, Vu C. In: The World Health Report 2003 - Shaping the Future. Beaglehole R, Irwin A, Prentice T, editor. World Health Organization, Geneva, Switzerland; 2003. Neglected global epidemics: three growing threats; pp. 83–102.
    1. Perkovic V, Huxley R, Wu Y, Prabhakaran PD, MacMahon S. The burden of blood pressure-related disease: a neglected priority in global health. Hypertension. 2007;50:991–997. doi: 10.1161/HYPERTENSIONAHA.107.095497.
    1. Donnison C. Blood pressure in African natives: its bearing on the aetiology of hyperpiesa and arteriosclerosis. Lancet. 1929;i:6–7.
    1. Opie LH, Seedat YK. Hypertension in sub-Saharan African populations. Circulation. 2005;112:3562–3568. doi: 10.1161/CIRCULATIONAHA.105.539569.
    1. Whitworth JA. World Health Organization ISoHWG; World Health Organization ISoHWG. 2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens. 2003;21:1983–1992.
    1. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J. ASCOT Investigators; ASCOT Investigators. Prevention of cardiovascular events with an amlodipine ± perindopril strategy compared with an atenolol ± thiazide strategy. The Anglo-Scandinavian Cardiac Outcomes Trial - Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895–906. doi: 10.1016/S0140-6736(05)67185-1.
    1. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velaquez EJ. ACCOMPLISH Trial Investigators; ACCOMPLISH Trial Investigators. Benazapril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417–2428. doi: 10.1056/NEJMoa0806182.
    1. Odili AN, Richart T, Thijs L, Kingue S, Boombhi HJ, Lemogoum D, Kaptue J, Kamden M, Mipinda JB, Omotoso BA, Kolo PM, Aderibigbe A, Ulasi II, Anisiuba BC, Ijoma CK, Ba SA, Ndiaye MB, Staessen JA, M'buyamba-Kabangu JR. NOAAH Investigators; NOAAH Investigators. Rationale and design of the Newer Versus Older Antihypertensive Agents In African Hypertensive Patients (NOAAH) trial. Blood Press. 2011;20:256–266. doi: 10.3109/08037051.2011.572614.
    1. World Medical Assembly. Declaration of Helsinki: recommendations guiding physicians in biomedical research involving human subjects. Bull Pan Am Health Organ. 1990;24:606–609.
    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P. et al.Guidelines for the management of arterial hypertension. The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. doi: 10.1097/HJH.0b013e3281fc975a.
    1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabet Care. 1999;22(suppl 1):S5–S19.
    1. Sokolow M, Lyon TP. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J. 1949;37:161–186. doi: 10.1016/0002-8703(49)90562-1.
    1. Casale PN, Devereux RB, Alonso DR, Campo E, Kligfield P. Improved sex-specific criteria of left ventricular hypertrophy for clinical and computer interpretation of electrocardiograms: validation with autopsy findings. Circulation. 1987;75:565–572. doi: 10.1161/01.CIR.75.3.565.
    1. Okin PM, Roman MJ, Devereux RB, Kligfield P. Electrocardiographic identification of increased left ventricular mass by simple voltage-duration products. J Am Coll Cardiol. 1995;24:417–423.
    1. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A, Vahanian A, Camm J, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P. et al.2007 guidelines for the management of arterial hypertension. Eur Heart J. 2007;28:1462–1536.
    1. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: the Omron M5-I and the Omron 705IT. Blood Press Monit. 2003;8:127–133. doi: 10.1097/00126097-200306000-00006.
    1. O'Brien E, Asmar R, Beilin L, Imai Y, Mancia G, Mengden T, Myers M, Padfield P, Palatini P, Parati G, Pickering T, Redon J, Staessen J, Stergiou G, Verdecchia P. European Society of Hypertension Working Group on Blood Pressure Monitoring; European Society of Hypertension Working Group on Blood Pressure Monitoring. Practice guidelines of the European Society of Hypertension for clinic, ambulatory and self blood pressure measurement. J Hypertens. 2005;23:697–701. doi: 10.1097/01.hjh.0000163132.84890.c4.
    1. Staessen JA, Byttebier G, Buntinx F, Celis H, O'Brien ET, Fagard R. Antihypertensive treatment based on conventional or ambulatory blood pressure measurement. A randomized controlled trial. Ambulatory Blood Pressure Monitoring and Treatment of Hypertension Investigators. JAMA. 1997;278:1065–1072. doi: 10.1001/jama.1997.03550130039034.
    1. Staessen JA, Den Hond E, Celis H, Fagard R, Keary L, Vandenhoven G, O'Brien ET. the Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators; the Treatment of Hypertension Based on Home or Office Blood Pressure (THOP) Trial Investigators. Antihypertensive treatment based on blood pressure measurement at home or in the physician's office. A randomized controlled trial. JAMA. 2004;291:955–964.
    1. Ibrahim MM, Rizk H, Appel LJ, El Aroussy W, Helmy S, Sharaf Y, Ashour Z, Kandil H, Rocella E, Whelton PK. Hypertension prevalence, awareness, treatment, and control in Egypt. Hypertension. 1995;26:886–890. doi: 10.1161/01.HYP.26.6.886.
    1. Damasceno A, Azevedo A, Silva-Matos C, Prista A, Diogo D, Lunet N. Hypertension prevalence, awareness, treatment, and control in Mozambique: urban/rural gap during epidemiological transition. Hypertension. 2009;54:77–83. doi: 10.1161/HYPERTENSIONAHA.109.132423.
    1. Costanzo S, Di Castelnuovo A, Zito F, Krogh V, Siani A, Arnout J, Cappuccio FP, Miller MA, van Dongen M, de Lorgeril M, de Gaetano G, Donati MB, Iacoviello L. European Collaborative Group of the IMMIDIET project; European Collaborative Group of the IMMIDIET project. Prevalence, awareness, treatment and control of hypertension in healthy unrelated male–female pairs of European regions: the dietary habit profile in European communities with different risk of myocardioal infarction – the impact of migration as a model of gene-environment interaction. J Hypertens. 2008;26:2303–2311. doi: 10.1097/HJH.0b013e328311ce04.
    1. Bertoia ML, Waring ME, Gupta PS, Roberts MB, Eaton CB. Implications of new hypertension guidelines in the United States. Hypertension. 2011;58:361–366. doi: 10.1161/HYPERTENSIONAHA.111.175463.
    1. Staessen JA, Wang JG, Thijs L. Cardiovascular prevention and blood pressure reduction: a meta-analysis. Lancet. 2001;358:1305–1315. doi: 10.1016/S0140-6736(01)06411-X. A published erratum appears in Lancet2002, 359:360.
    1. Turnbull F. Blood Pressure Lowering Treatment Trialists' Collaboration; Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet. 2003;362:1527–1535.
    1. Staessen JA, Li Y, Thijs L, Wang JG. Blood pressure reduction and cardiovascular prevention: an update including the 2003–2004 secondary prevention trials. Hypertens Res. 2005;28:385–407. doi: 10.1291/hypres.28.385.
    1. Verdecchia P, Reboldi G, Angeli A, Gattobigio R, Bentivoglio M, Thijs L, Staessen JA, Porcellati C. Angiotensin-converting enzyme inhibitors and calcium channel blockers for coronary heart disease and stroke prevention. Hypertension. 2005;46:386–392. doi: 10.1161/01.HYP.0000174591.42889.a2.
    1. Staessen JA, Thijs L, Fagard R, Celis H, Birkenhäger WH, Bulpitt CJ, de Leeuw PW, Fletcher AE, Forette F, Leonetti G, McCormack P, Nachev C, O'Brien E, Rodicio JL, Rosenfeld J, Sarti C, Tuomilehto J, Webster J, Yodfat Y, Zanchetti A. Systolic Hypertension in Europe (Syst-Eur) Trial Investigators; Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Effects of immediate versus delayed antihypertensive therapy on outcome in the Systolic Hypertension in Europe Trial. J Hypertens. 2004;22:847–857. doi: 10.1097/00004872-200404000-00029.
    1. Cooper RS, Rotimi CN, Kaufman JS, Muna WFT, Mensah GA. Hypertension treatment and control in sub-Saharan Africa: the epidemiological basis for policy. Br Med J. 1998;316:614–617. doi: 10.1136/bmj.316.7131.614.
    1. M'Buyamba-Kabangu JR, Biswika RT, Thijs L, Tshimanga GM, Ngalula FM, Disashi T, Kayembe PK, Richart T, M'buyamba-Kayamba JR, Lepira FB, Staessen JA. In-hospital mortality among black patients admitted for hypertension-related disorders in Mbuji Mayi, Congo. Am J Hypertens. 2009;22:643–648. doi: 10.1038/ajh.2009.47.
    1. Arodiwe EB, Ike SO, Nwokediuko SC. Case fatality among hypertension-related admissions in Enugu, Nigeria. Niger J Clin Pract. 2009;12:153–156.
    1. Seedat YK, Croasdale MA, Milne FJ, Opie LH, Pinkney-Atkinson VJ, Rayner BL, Veriava Y. Guideline Committee, Southern African Hypertension Society Directorate, Chronic Diseases, Disabilities and Geriatrics, National Department of Health; Guideline Committee, Southern African Hypertension Society Directorate, Chronic Diseases, Disabilities and Geriatrics, National Department of Health. South African Hypertension Guideline 2006. S Afr Med J. 2006;96:337–362.
    1. Lemogoum D, Seedat YK, Mabadeje AFB, Mendis S, Bovet P, Onwubere B, Blacket KN, Lenfant C, M'Buyamba-Kabangu JR, Block P, Belhocine M, Degaute JP. International Forum for Hypertension Control and Prevention in Africa; International Forum for Hypertension Control and Prevention in Africa. Recommendations for prevention, diagnosis and management of hypertension and cardiovascular risk factors in sub-Saharan Africa. J Hypertens. 2003;21:1993–2000. doi: 10.1097/00004872-200311000-00003.
    1. Guidelines Committee. Guidelines for the management of hypertension in Nigeria. Ezu Books Ltd, Enugu, Nigeria; 2005.
    1. Chobanian AV, Bakris GL, Black BK, Cushman WC, Green LA, Izzo JL, Jones DW, Materson BJ, Oparil S, Wright JT, Roccella EJ. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2.
    1. Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, Jamerson KA, Jones WE, Haywood J, Maxey R, Ofili EO, Saunders E, Schiffrin EL, Sica DA, Sowers JR, Vidt DG. Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks; Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003;163:525–541. doi: 10.1001/archinte.163.5.525.
    1. Flack JM, Sica DA, Bakris G, Brown AL, Ferdinand KC, Grimm RH, Hall WD, Jones WE, Kountz DS, Lea JP, Nasser S, Nesbitt SD, Saunders E, Scisney-Matlock M, Jamerson KA. International Society on Hypertension in Blacks; International Society on Hypertension in Blacks. Management of hypertension in Blacks: an update of the International Society of Hypertension in Blacks Consensus Statement. Hypertension. 2010;56:780–800. doi: 10.1161/HYPERTENSIONAHA.110.152892.
    1. Brown MJ, Cruickshank JM, Dominiczak AF, MacGregor GA, Poulter NR, Russell GI, Thom S, Williams B. Better blood pressure control: how to combine drugs? J Hum Hypertens. 2003;17:81–86. doi: 10.1038/sj.jhh.1001511.
    1. Brown MJ. Hypertension and ethnic group. Br Med J. 2006;332:833–836. doi: 10.1136/bmj.332.7545.833.
    1. Khan JM, Beevers DG. Management of hypertension in ethnic minorities. Heart. 2005;91:1105–1109. doi: 10.1136/hrt.2004.044560.
    1. Zachariah PK, Messerli FH, Mroczek W. Low-dose bisoprolol/hydrochlorothiazide: an option in first-line antihypertensive treatment. Clin Ther. 1993;15:779–787.
    1. Papademetriou V, Prisant M, Neutel JM, Weir MR. Efficacy of low-dose combination of bisoprolol/hydrochlorothiazide compared with amlodipine and enalapril in men and women with essential hypertension. Am J Cardiol. 1998;81:1363–1365. doi: 10.1016/S0002-9149(98)00169-6.
    1. Prisant LM, Neutel JM, Ferdinand K, Papademetriou V, DeQuattro V, Hall WD, Weir MR. Low-dose combination therapy as first-line hypertension treatment for Blacks and Nonblacks. J Natl Med Assoc. 1999;91:40–48.
    1. Devasenapathy N, Singh K, Prabhakaran D. Conduct of clinical trials in developing countries: a perspective. Curr Opin Cardiol. 2009;24:295–300. doi: 10.1097/HCO.0b013e32832af21b.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다